Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 1, 2007, Pages 6-12

  Willemsen, Judith M ^a,f   Westerink, Jan W ^b   Dallinga Thie, Geesje M ^c   Van Zonneveld, Anton Jan ^d   Gaillard, Carlo A ^e   Rabelink, Ton J ^d   De Koning, Eelco J P ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b GELRE HOSPITALS   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MEANDER MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Angiotensin receptor blockade; Diabetes mellitus; Endothelial function; Hyperglycemia; Hyperglycemic clamp; Leucocyte

Indexed keywords

CYTOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ADULT; ARTERY BLOOD FLOW; ARTICLE; BRACHIAL ARTERY; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETES MELLITUS; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; EX VIVO STUDY; GLUCOSE TOLERANCE TEST; HUMAN; HYPERGLYCEMIA; HYPERGLYCEMIC CLAMP; LEUKOCYTE; MALE; NORMAL HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CYTOKINES; ENDOTHELIUM; HUMANS; HYPERGLYCEMIA; INFLAMMATION MEDIATORS; LEUKOCYTES; MALE; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; VALINE;

EID: 33846633713     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31802b31a7     Document Type: Article

References (37)

1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59:8-13.
2. Creager MA, Luscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108:1527-1532.
3. Cosentino F, Hishikawa K, Katusic ZS, et al. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation. 1997;96:25-28.
4. Beckman JA, Goldfine AB, Gordon MB, et al. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation. 2001;103:1618-1623.
5. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97:1695-1701.
6. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
7. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586-1593.
8. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
9. Laursen JB, Rajagopalan S, Galis Z, et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997;95:588-593.
10. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
11. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R277-R297.
12. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067-2072.
13. Reed AS, Charkoudian N, Vella A, et al. Forearm vascular control during acute hyperglycemia in healthy humans. Am J Physiol Endocrinol Metab. 2004;286:E472-E480.
14. van Etten RW, de Koning EJ, Verhaar MC, et al. Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia. 2002;45:1004-1010.
15. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium- dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1992;35:771-776.
16. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567-574.
17. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813-823.
18. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103-1107.
19. Takahashi T, Hato F, Yamane T, et al. Activation of human neutrophil by cytokine-activated endothelial cells. Circ Res. 2001;88:422-429.
20. de la Harpe J, Nathan CF. Adenosine regulates the respiratory burst of cytokine-triggered human neutrophils adherent to biologic surfaces. J Immunol. 1989;143:596-602.
21. Lindemann A, Riedel D, Oster W, et al. Granulocyte/macrophage colony-stimulating factor induces interleukin 1 production by human polymorphonuclear neutrophils. J Immunol. 1988;140:837-839.
22. Fan J, Frey RS, Rahman A, et al. Role of neutrophil NADPH oxidase in the mechanism of tumor necrosis factor-alpha-induced NF-kappa B activation and intercellular adhesion molecule-1 expression in endothelial cells. J Biol Chem. 2002;277:3404-3411.
23. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49:1939-1945.
24. Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab. 2003;88:4496-4501.
25. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev. 1990;70:427-451.
26. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004;109:1718-1723.
27. Sugano R, Matsuoka H, Haramaki N, et al. Polymorphonuclear leukocytes may impair endothelial function: results of crossover randomized study of lipid-lowering therapies. Arterioscler Thromb Vasc Biol. 2005;25:1262-1267.
28. Madjid M, Awan I, Willerson JT, et al. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol. 2004;44:1945-1956.
29. Friedman GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction. N Engl J Med. 1974;290:1275-1278.
30. Golovchenko I, Goalstone ML, Watson P, et al. Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappa B induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res. 2000;87:746-752.
31. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105:576-582.
32. Hu RM, Levin ER, Pedram A, et al. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes. 1993;42:351-358.
33. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001;86:3257-3265.
34. Aljada A, Ghanim H, Saadeh R, et al. Insulin inhibits NFkappa B and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab. 2001;86:450-453.
35. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 2000;101:676-681.
36. Hermann C, Assmus B, Urbich C, et al. Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:402-409.
37. Rask-Madsen C, Ihlemann N, Krarup T, et al. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes. 2001;50:2611-2618.